Products and Technology

BioProcess – enabling tomorrow’s therapeutics

Downstream processing represents a significant bottleneck in the biopharmaceutical industry. To meet growing demand, a robust and scalable platform is required that can effectively isolate a wide range of biotherapeutics.

Upfront’s Rhobust® universal processing platform enables customers to efficiently recover and purify monoclonal antibodies, therapeutic proteins and other biomolecules direct from blood plasma or bioreactors, under cGMP-compliant conditions, and up to commercial scale.

Brochures

Video

Presentations

Articles

Press Releases

29 October 2009
Improved Downstream Processing at Richter-He...

16 June 2009
Upfront Chromatography licenses use of EBA t...

News Archive

Published Articles

24 November 2009
Recent Developments in the production of MAb...

24 November 2009
Biogen: Improving DSP Productivity

Articles Archive